Clarus Therapeutics: Phase 3 – REXTORO(R) for Men With Hypogonadism

Clarus Therapeutics, Inc., a men’s health specialty pharmaceutical company focused on the development and commercialization of REXTORO ( (Testosterone Undecanoate), an oral testosterone (T) replacement product, today presented Phase 3 clinical data from two studies that support the safety and efficacy of REXTORO for T-replacement therapy in men with hypogonadism. These results are being presented from 1-3 p.m.

Biocom/LA BioMed partners with San Diego International Airport Art Program

Biocom, the association for the Southern California life science community, and the San Diego International Airport Art Program announce the return of the cell culture exhibit, a showcase of art from microscopic research contributing to life-changing breakthroughs taking place in the Southern California region.

NovaDigm Strengthens Candida Vaccine Portfolio

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that it has acquired the rights, in four separate transactions, to three well-studied Candida vaccine antigens, significantly bolstering the Company’s Candida vaccine pipeline.

LA BioMed Receives Community Service Award – Palos Verdes Peninsula Coordinating Council Honors the Institute

The Palos Verdes Peninsula Coordinating Council presented the Los Angeles Biomedical Research Institute (LA BioMed) with its Community Service Award on May 22, an annual honor it gives to an organization with programs that “greatly benefit the community.”

The Council, formed in 1956, provides programs of interest to the community and publishes an updated calendar of nonprofit events as a service the community. It has been presenting the Community Service Award to local organizations since 1961.

MRSA Rates Varied Dramatically Across Geographic Areas – Researchers studied LA, San Francisco, Chicago, New York and Raleigh-Durham

The rates of community-onset methicillin-resistant Staphylococcus aureus (CO-MRSA) varied dramatically among academic medical centers in California, New York, Illinois and North Carolina, suggesting there is not a uniform change in the “national epidemic” of the “superbug” that has generated extensive public health concern over the past decade, according to a new study.